President Donald J. Trump is reportedly on the verge of removing U.S. Food and Drug Administration Commissioner Marty Makary from his post.
The potential removal of the agency head signals a deepening crisis within the federal body responsible for overseeing food and drug safety. Such a leadership change suggests that the White House is dissatisfied with the current trajectory of the agency's operations.
Makary was installed as the FDA commissioner in 2025 [2]. However, his tenure has been marked by significant internal agency turmoil and increasing criticism regarding his leadership style. Reports published on May 8, 2026 [1], indicate that the administration is moving toward a change in leadership.
Sources said that the friction stems from concerns over recent policy changes and budget cuts. The Department of Health and Human Services reportedly pushed the president to fire Makary, citing concerns tied to these cuts and the resulting instability within the agency [3].
There is a discrepancy regarding the actual impact of these financial reductions. Some reports suggest the cuts did not affect the agency's ability to function [4], while other sources said that the budget issues contributed directly to the turmoil that has left Makary on the ropes [3].
The FDA is tasked with protecting public health by ensuring the safety and efficacy of medicines, and medical devices. The current instability at the top of the organization comes at a time when the agency is managing critical regulatory frameworks and public health mandates. The White House has not officially confirmed the timing of the removal, but sources close to the matter said the decision is imminent [3].
“President Donald J. Trump is reportedly on the verge of removing U.S. Food and Drug Administration Commissioner Marty Makary”
The potential removal of Marty Makary reflects a volatile period for the FDA, where budget constraints and policy shifts have created a rift between the agency's leadership and the Department of Health and Human Services. If the administration replaces the commissioner, it may signal a pivot in how the U.S. government intends to handle drug approvals and food safety regulations, potentially prioritizing different administrative goals over the current leadership's approach.
